Zealand Pharma and Pepscan awarded EU grant of EUR 0.9 million for the joint development of peptide drugs

24-Mar-2011 - Netherlands

Zealand Pharma and Pepscan Holding NV announced the joint award of an EU research and development grant of EUR 860,000. The grant is awarded under the EUREKA Eurostars programme for the joint development of dual acting peptide drugs. The application by Zealand Pharma and Pepscan ranked no. 5 out of approximately 350 applications. With the collaboration, the two companies combine their competences to develop drugs to better treat chronic inflammations and gastrointestinal diseases, including Inflammatory Bowel Disease.

The grant awarded to Zealand Pharma and Pepscan covers a two-year development period, which is expected to lead to the identification of a lead dual acting peptide drug candidate ready for preclinical development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances